Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). by Clarke, P, Gray, A, Adler, A, Stevens, R, Raikou, M, Cull, C, Stratton, I, Holman, R

An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54). by Gray, A, Clarke, P, Raikou, M, Adler, A, Stevens, R, Neil, H, Cull, C, Stratton, I, Holman, R

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom... by Gray, A, Raikou, M, McGuire, A, Fenn, P, Stevens, R, Cull, C, Stratton, I, Adler, A, Holman, R, Turner, R

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom... by Gray, A, Raikou, M, McGuire, A, Fenn, P, Stevens, R, Cull, C, Stratton, I, Adler, A, Holman, R, Turner, R

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). by Raikou, M, McGuire, A, Colhoun, H, Betteridge, D, Durrington, P, Hitman, G, Neil, H, Livingstone, S, Charlton-Menys, V, Fuller, J

Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation by Raikou, M, McGuire, A, Colhoun, H, Betteridge, J, Durrington, P, Hitman, G, Neil, A, Livingstone, S, Thomason, M, Mackness, M, Charlton-Menys, V, Fuller, J, Investigato, C